GreenLight Biosciences Holdings (GRNAW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GreenLight Biosciences Holdings (GRNAW) trades at $0.022. GreenLight Biosciences Holdings is a biotechnology company focused on developing RNA-based solutions for human health and agriculture. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for GRNAW: GRNAW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GRNAW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on GRNAW.
How is this calculated? →GreenLight Biosciences Holdings (GRNAW) Healthcare & Pipeline Overview
GreenLight Biosciences Holdings pioneers RNA-based solutions for human health and agriculture, offering mRNA vaccines, therapeutics, and crop protection products. With a focus on innovation and sustainability, the company addresses critical needs in diverse markets, striving to improve global health and agricultural practices amidst evolving industry dynamics.
What Is the Investment Thesis for GRNAW?
GreenLight Biosciences Holdings presents a compelling investment thesis centered on its innovative RNA platform and diverse applications in human health and agriculture. The company's focus on mRNA vaccines and therapeutics, coupled with its sustainable agricultural solutions, positions it to capitalize on growing market demand for RNA-based products. Key value drivers include successful clinical trials for its mRNA vaccine candidates and regulatory approvals for its agricultural products. However, the company's negative P/E ratio of -0.24 and a significant negative profit margin of -2616.8% indicate substantial financial challenges. The company's ability to secure additional funding, achieve commercial success with its products, and manage operational costs will be critical to its long-term viability. Upcoming milestones include advancing its mRNA vaccine pipeline and expanding its agricultural product offerings, while potential risks include regulatory hurdles and competition from established players in the biotechnology industry.
Based on FMP financials and quantitative analysis
GRNAW Key Highlights
GreenLight Biosciences Holdings operates in the biotechnology sector, focusing on RNA-based solutions for human health and agriculture.
- The company's product portfolio includes mRNA vaccines and therapeutics for human health, and RNA-based crop protection products for agriculture.
- GreenLight Biosciences Holdings was founded in 2008 and is headquartered in Medford, Massachusetts.
- The company's gross margin is 100.0%, indicating a strong potential for profitability if sales volume increases.
- The company's negative P/E ratio of -0.24 and profit margin of -2616.8% suggest it is currently not profitable.
Who Are GRNAW's Competitors?
GRNAW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DRTSW Alpha Tau Medical Ltd. | $3.90 | +3.45% | $1.51B | — |
| EQRXW EQRx, Inc. | $0.05 | +0.00% | $1.14B | 47 |
| GRNA GreenLight Biosciences Holdings | $0.30 | -0.03% | $45.4M | 57 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GRNAW's Key Strengths?
Proprietary RNA technology platform
- Sustainable solutions for agriculture
- Diverse applications in human health and agriculture
- Experienced management team
What Are GRNAW's Weaknesses?
Negative P/E ratio and profit margin
- Limited commercialized products
- Reliance on external funding
- High R&D costs
What Could Drive GRNAW Stock Higher?
Clinical trial results for mRNA vaccine candidates.
- Regulatory approvals for agricultural RNA products.
- Strategic partnerships and collaborations to expand market reach.
- Expansion of product offerings and distribution channels.
What Are the Key Risks for GRNAW?
Competition from established biotechnology companies with greater resources.
- Regulatory hurdles and delays in product approvals.
- Intellectual property challenges and patent disputes.
- Reliance on external funding and potential dilution of shareholder value.
- Economic downturn and reduced demand for healthcare and agricultural products.
What Are the Growth Opportunities for GRNAW?
- Expansion of mRNA Vaccine Pipeline: GreenLight Biosciences has the opportunity to expand its mRNA vaccine pipeline to target a broader range of infectious diseases. Successful development and commercialization of new mRNA vaccines could generate significant revenue for the company. This growth opportunity is ongoing, with continuous research and development efforts focused on identifying and validating new vaccine targets.
- Commercialization of Agricultural RNA Products: GreenLight Biosciences can capitalize on the growing demand for sustainable agricultural solutions by commercializing its RNA-based crop protection products. The global market for biopesticides is expected to reach $10 billion by 2027, driven by increasing concerns about the environmental impact of traditional chemical pesticides. Successful market penetration and adoption of GreenLight Biosciences's agricultural products could drive significant revenue growth. This growth opportunity is ongoing, with continuous efforts to expand product offerings and distribution channels.
- Strategic Partnerships and Collaborations: GreenLight Biosciences can leverage strategic partnerships and collaborations to accelerate its research and development efforts and expand its market reach. Collaborating with established pharmaceutical companies or agricultural companies could provide access to additional funding, expertise, and distribution networks. These partnerships can help the company to bring its products to market more quickly and efficiently. This growth opportunity is ongoing, with continuous efforts to identify and pursue strategic partnerships.
- Geographic Expansion: GreenLight Biosciences has the opportunity to expand its operations into new geographic markets, particularly in developing countries where there is a high unmet need for affordable healthcare and sustainable agriculture solutions. Expanding into new markets can increase the company's customer base and revenue streams. This growth opportunity is ongoing, with continuous efforts to assess market opportunities and establish a presence in new regions.
- Development of Novel RNA-Based Therapeutics: GreenLight Biosciences can leverage its RNA platform to develop novel therapeutics for a range of diseases, including cancer, autoimmune disorders, and genetic diseases. The market for RNA-based therapeutics is expected to reach $25 billion by 2028, driven by advancements in RNA technology and increasing demand for targeted therapies. Successful development and commercialization of new RNA-based therapeutics could generate significant revenue for the company. This growth opportunity is ongoing, with continuous research and development efforts focused on identifying and validating new therapeutic targets.
What Are GRNAW's Competitive Advantages?
- Proprietary RNA Technology Platform: GreenLight Biosciences has developed a proprietary RNA technology platform that enables the rapid and efficient development of RNA-based products.
- Sustainable Solutions: The company's RNA-based crop protection products offer a sustainable alternative to traditional chemical pesticides, which can be harmful to the environment and human health.
- Diverse Applications: GreenLight Biosciences's RNA technology has diverse applications in human health and agriculture, providing multiple avenues for growth and revenue generation.
What Does GRNAW Do?
GreenLight Biosciences Holdings, founded in 2008 and headquartered in Medford, Massachusetts, is a biotechnology company dedicated to developing and commercializing RNA-based solutions for significant global challenges. The company operates at the intersection of human health and agriculture, leveraging its proprietary RNA platform to create innovative products that address unmet needs in both sectors. In human health, GreenLight Biosciences focuses on mRNA vaccines and therapeutics, aiming to develop novel treatments for a range of diseases. Their approach leverages the versatility of mRNA technology to create targeted and effective therapies. In agriculture, the company develops RNA-based products to protect crops and honeybees, offering sustainable alternatives to traditional chemical pesticides. These products are designed to be environmentally friendly and highly effective, contributing to more sustainable agricultural practices. GreenLight Biosciences's commitment to innovation and sustainability is central to its mission. The company strives to develop products that not only improve human health and agricultural productivity but also minimize environmental impact. With a team of experienced scientists and engineers, GreenLight Biosciences is positioned to be a leader in the rapidly evolving field of RNA technology.
What Products and Services Does GRNAW Offer?
- Develops mRNA vaccines and therapeutics for human health.
- Creates RNA-based products to protect crops from pests and diseases.
- Offers sustainable alternatives to traditional chemical pesticides.
- Manufactures and sells RNA products for agriculture.
- Researches and develops new applications for RNA technology.
- Aims to improve global health and agricultural practices through innovative RNA solutions.
How Does GRNAW Make Money?
- Develops and commercializes RNA-based products for human health and agriculture.
- Generates revenue through the sale of mRNA vaccines, therapeutics, and crop protection products.
- Partners with pharmaceutical and agricultural companies for research, development, and distribution.
- Focuses on innovation and sustainability to create value for customers and shareholders.
What Industry Does GRNAW Operate In?
GreenLight Biosciences Holdings operates within the rapidly evolving biotechnology industry, which is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The market for RNA-based therapeutics and vaccines is experiencing significant growth, driven by advancements in mRNA technology and increasing demand for novel treatments for infectious diseases and other health conditions. In agriculture, there is a growing need for sustainable crop protection solutions, creating opportunities for companies like GreenLight Biosciences to offer environmentally friendly alternatives to traditional pesticides. The company faces competition from established biotechnology companies and emerging players in the RNA space.
Who Are GRNAW's Key Customers?
- Pharmaceutical companies seeking novel mRNA vaccines and therapeutics.
- Agricultural companies and farmers looking for sustainable crop protection solutions.
- Government agencies and organizations focused on public health and food security.
- Research institutions and universities conducting studies on RNA technology.
Company Profile
GreenLight Biosciences Holdings operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Medford, US.
GRNAW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, which often signals positive expectations among leadership.
- Community sentiment has shown increasing optimism, with discussions highlighting potential breakthroughs in their RNA technology.
- The market is reacting positively to recent partnerships that could enhance their research capabilities and market reach.
- GreenLight's focus on sustainable agriculture aligns well with growing environmental concerns, attracting interest from socially responsible investors.
Bear Case
- Concerns about the scalability of their technology have been raised, leading some investors to question long-term viability.
- Recent earnings reports have not met market expectations, causing skepticism about the company's growth trajectory.
- Community discussions indicate a divide, with some investors expressing doubts about the competitive landscape in the biotech sector.
- Regulatory hurdles in the biotech field could delay product launches, creating uncertainty around future revenue streams.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GRNAW Latest News
No recent news available for GRNAW.
GRNAW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRNAW.
Price Targets
Wall Street price target analysis for GRNAW.
GRNAW MoonshotScore
What does this score mean?
The MoonshotScore rates GRNAW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
What Investors Ask About GreenLight Biosciences Holdings (GRNAW) — Healthcare
What does GreenLight Biosciences Holdings do?
GreenLight Biosciences Holdings is a biotechnology company that manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. In human health, they focus on mRNA vaccines and therapeutics. For agriculture, they develop RNA products to protect honeybees and crops, offering sustainable alternatives to traditional chemical pesticides.
What are the main risks for GRNAW?
GreenLight Biosciences Holdings faces several key risks, including intense competition from established biotechnology companies with greater financial and research resources. Regulatory hurdles and potential delays in product approvals pose another significant risk, as the company's success depends on the timely approval of its mRNA vaccines and agricultural products. Intellectual property challenges and patent disputes could also impact its competitive position.
What are the key factors to evaluate for GRNAW?
Evaluate GRNAW on fundamentals, analyst consensus, and risk factors. GreenLight Biosciences Holdings presents a compelling investment thesis centered on its innovative RNA platform and diverse applications in human health and agriculture. Not financial advice.
How frequently does GRNAW data refresh on this page?
GRNAW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GRNAW's recent stock price performance?
GreenLight Biosciences Holdings (GRNAW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary RNA technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GRNAW overvalued or undervalued right now?
GreenLight Biosciences Holdings (GRNAW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GRNAW before investing?
Before investing in GreenLight Biosciences Holdings (GRNAW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GRNAW to a portfolio?
Key strength of GreenLight Biosciences Holdings (GRNAW): Proprietary RNA technology platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide additional insights.